These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 18308931)

  • 1. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
    Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular synergy underlies the co-occurrence patterns and phenotype of
    Dovey OM; Cooper JL; Mupo A; Grove CS; Lynn C; Conte N; Andrews RM; Pacharne S; Tzelepis K; Vijayabaskar MS; Green P; Rad R; Arends M; Wright P; Yusa K; Bradley A; Varela I; Vassiliou GS
    Blood; 2017 Oct; 130(17):1911-1922. PubMed ID: 28835438
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance.
    Alcalay M; Tiacci E; Bergomas R; Bigerna B; Venturini E; Minardi SP; Meani N; Diverio D; Bernard L; Tizzoni L; Volorio S; Luzi L; Colombo E; Lo Coco F; Mecucci C; Falini B; Pelicci PG
    Blood; 2005 Aug; 106(3):899-902. PubMed ID: 15831697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
    Rau R; Brown P
    Hematol Oncol; 2009 Dec; 27(4):171-81. PubMed ID: 19569254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
    Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
    Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence and clinical significance of nucleophosmin mutations in childhood AML.
    Brown P; McIntyre E; Rau R; Meshinchi S; Lacayo N; Dahl G; Alonzo TA; Chang M; Arceci RJ; Small D
    Blood; 2007 Aug; 110(3):979-85. PubMed ID: 17440048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
    Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
    Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOX expression patterns identify a common signature for favorable AML.
    Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
    Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.
    Rau R; Magoon D; Greenblatt S; Li L; Annesley C; Duffield AS; Huso D; McIntyre E; Clohessy JG; Reschke M; Pandolfi PP; Small D; Brown P
    Exp Hematol; 2014 Feb; 42(2):101-13.e5. PubMed ID: 24184354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
    Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
    Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of specific microRNA and their targets in acute myeloid leukemia.
    Cammarata G; Augugliaro L; Salemi D; Agueli C; La Rosa M; Dagnino L; Civiletto G; Messana F; Marfia A; Bica MG; Cascio L; Floridia PM; Mineo AM; Russo M; Fabbiano F; Santoro A
    Am J Hematol; 2010 May; 85(5):331-9. PubMed ID: 20425795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status.
    Faraoni I; Laterza S; Ardiri D; Ciardi C; Fazi F; Lo-Coco F
    J Hematol Oncol; 2012 Jun; 5():26. PubMed ID: 22681934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
    Quentmeier H; Martelli MP; Dirks WG; Bolli N; Liso A; Macleod RA; Nicoletti I; Mannucci R; Pucciarini A; Bigerna B; Martelli MF; Mecucci C; Drexler HG; Falini B
    Leukemia; 2005 Oct; 19(10):1760-7. PubMed ID: 16079892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.
    Bryant A; Palma CA; Jayaswal V; Yang YW; Lutherborrow M; Ma DD
    Mol Cancer; 2012 Feb; 11():8. PubMed ID: 22348345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.
    Seyyedi SS; Soleimani M; Yaghmaie M; Ajami M; Ajami M; Pourbeyranvand S; Alimoghaddam K; Akrami SM
    Tumour Biol; 2016 Apr; 37(4):4841-7. PubMed ID: 26526573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.